Cogentum client Acrux today announced one of the biggest licensing  deals in Australian Biotech history. The deal with Eli Lilly ranks up there as one of the biggest outcomes for an Australian biotech. From the announcements you will see that this is a superb result for any Australian company seeking to license it’s technology.

Cogentum worked [...]

[Read more →]

For the last 8 months we have been working with Neopec, a new company that is commercialising a revolutionary approach to breast reconstruction using technology developed at Melbourne, Australia’s Bernard O’Brien Institute of Microsurgery and the Australian Tissue Engineering Center.
Neopec will allow women who have been through the trauma of breast cancer and mastectomy to re-grow [...]

[Read more →]

Great news is continuing to emerge from the Australian biotech sctor.
We are glad to see that one of our clients, Acrux, is leading the charge as it continues to build a cogent story for its investors and the market.
Equally pleasing is the rapid progress of Universal Biosensors (sadly, not a client!). This company is, in our [...]

[Read more →]

The following piece appeared in September 28th edition of Bioshares #330, Australia’s leading analysis and commentary on the Biotech sector. It summarises our out take on the 2009 Bioshares conference held at Thredbo in September.

Don’t worry about your Technology, show me the Strategy

The 2009 Thredbo summit graphically illustrated why strategy is becoming increasingly more valuable [...]

[Read more →]

We presented recently (June 15th &16th) at the Australian Medical Technology conference held in Sydney. The conference brought together some of the regions leading firms and discussed a wide range of issues.
I was fortunate to present, in conjunction with David James from Invetech and Travis Hardy from ARRK on Design for Manufacturing and how many [...]

[Read more →]

For some time we have heard media, political opposition parties and lobby and community groups complain about the hospital bed crisis.
Put simply, there are not enough Hospital beds for those patients who need them.
However,  the solution that is often put forward - building new hospitals, commissioning new wards, creating new beds is not the answer.
In [...]

[Read more →]

Sometimes a great idea has no market.
What? I hear you say? Burn him at the stake the heretic!
But it’s true, not all great ideas have a market!
The failure of retractable syringes to gain a foothold is a case in point. One company we know of developed a great piece of technology that allowed the needle [...]

[Read more →]

The recent announcement by Brisbane based Progen that they would discontinue their PI-88 drug development comes as a wake up call for the entire Biotech industry.
The Board of Progen announced that the reasons underlying this about face in strategy were based on issues around patient recruitment, regulatory issues and clinical site initiation amongst others. We [...]

[Read more →]

Many biotech company’s take a view that FDA approval will provide them with instantaneous market acceptance. As one veteran of the industry told us, “Historically, if you get FDA approval your sales will exponentially go through the roof”. As a result, for Biotech’s, getting the nod from the FDA was seen as carte blanche to [...]

[Read more →]